Downregulation of TIGIT Expression in FOXP3+Regulatory T Cells in Acute Coronary Syndrome

References

• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Ralapanawa U, Sivakanesan R. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health. 2021;11(2):169–177. doi:10.2991/jegh.k.201217.001
   PubMed Web of Science ®Google Scholar
• Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113–131. doi:10.1093/eurheartj/ehaa099
   PubMed Web of Science ®Google Scholar
• Sincer I, Gunes Y, Mansiroglu AK, Cosgun M, Aktas G. Association of mean platelet volume and red blood cell distribution width with coronary collateral development in stable coronary artery disease. Postepy Kardiol Interwencyjnej. 2018;14(3):263–269. doi:10.5114/aic.2018.78329
   PubMed Web of Science ®Google Scholar
• Sincer I, Gunes Y, Mansiroglu AK, Aktas G. Differential value of eosinophil count in acute coronary syndrome among elderly patients. Aging Male. 2020;23(5):958–961. doi:10.1080/13685538.2019.1643310
   PubMed Web of Science ®Google Scholar
• Sincer I, Mansiroglu AK, Erdal E, Cosgun M, Aktas G, Gunes Y. Could platelet distribution width predict coronary collateral development in stable coronary artery disease? North Clin Istanb. 2020;7(2):112–117. doi:10.14744/nci.2019.47374
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Orekhov AN, Bobryshev YV. Immune-inflammatory responses in atherosclerosis: role of an adaptive immunity mainly driven by T and B cells. Immunobiology. 2016;221(9):1014–1033. doi:10.1016/j.imbio.2016.05.010
   PubMed Web of Science ®Google Scholar
• Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38(6):1092–1104. doi:10.1016/j.immuni.2013.06.009
   PubMed Web of Science ®Google Scholar
• Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17(7):387–401. doi:10.1038/s41569-020-0352-5
   PubMed Web of Science ®Google Scholar
• Mao X, Zhu R, Zhang F, et al. IL-37 plays a beneficial role in patients with acute coronary syndrome. Mediators Inflamm. 2019;2019:9515346. doi:10.1155/2019/9515346
   PubMed Web of Science ®Google Scholar
• Lin YZ, Wu BW, Lu ZD, et al. Circulating Th22 and Th9 levels in patients with acute coronary syndrome. Mediators Inflamm. 2013;2013:635672. doi:10.1155/2013/635672
   PubMed Web of Science ®Google Scholar
• Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127(1):89–97. doi:10.1016/j.clim.2008.01.009
   PubMed Web of Science ®Google Scholar
• Mohr A, Malhotra R, Mayer G, Gorochov G, Miyara M. Human FOXP3+ T regulatory cell heterogeneity. Clin Transl Immunol. 2018;7(1):e1005. doi:10.1002/cti2.1005
   PubMed Web of Science ®Google Scholar
• Meng K, Zhang W, Zhong Y, et al. Impairment of Circulating CD4⁺CD25⁺GARP⁺ regulatory T cells in patients with acute coronary syndrome. Cell Physiol Biochem. 2014;33(3):621–632. doi:10.1159/000358639
   PubMedGoogle Scholar
• Mitsuiki N, Schwab C, Grimbacher B. What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev. 2019;287(1):33–49. doi:10.1111/imr.12721
   PubMed Web of Science ®Google Scholar
• Kumar P, Bhattacharya P, Prabhakar BS. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun. 2018;95:77–99. doi:10.1016/j.jaut.2018.08.007
   PubMed Web of Science ®Google Scholar
• Joller N, Lozano E, Burkett PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569–581. doi:10.1016/j.immuni.2014.02.012
   PubMed Web of Science ®Google Scholar
• Wang F, Hou H, Wu S, et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol. 2015;45(10):2886–2897. doi:10.1002/eji.201545480
   PubMed Web of Science ®Google Scholar
• Luo Q, Li X, Fu B, et al. Decreased expression of TIGIT in NK cells correlates negatively with disease activity in systemic lupus erythematosus. Int J Clin Exp Pathol. 2018;11(5):2408–2418.
   PubMed Web of Science ®Google Scholar
• Luo Q, Deng Z, Xu C, et al. Elevated Expression of Immunoreceptor Tyrosine-Based Inhibitory Motif (TIGIT) on T Lymphocytes is Correlated with Disease Activity in Rheumatoid Arthritis. Med Sci Monit. 2017;23:1232–1241. doi:10.12659/msm.902454
   PubMed Web of Science ®Google Scholar
• Mao L, Hou H, Wu S, et al. TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus. Immunology. 2017;151(3):280–290. doi:10.1111/imm.12715
   PubMed Web of Science ®Google Scholar
• Wang FF, Wang Y, Wang L, Wang TS, Bai YP. TIGIT expression levels on CD4+ T cells are correlated with disease severity in patients with psoriasis. Clin Exp Dermatol. 2018;43(6):675–682. doi:10.1111/ced.13414
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang J, Zhou X, et al. Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia. J Cell Biochem. 2014;115(11):1918–1927. doi:10.1002/jcb.24862
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.001
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053–4062. doi:10.1172/JCI81187
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi:10.1093/eurheartj/ehz425
   PubMed Web of Science ®Google Scholar
• Lee DJ. The relationship between TIGIT+ regulatory T cells and autoimmune disease. Int Immunopharmacol. 2020;83:106378. doi:10.1016/j.intimp.2020.106378
   PubMed Web of Science ®Google Scholar
• Liu K, Li T, Huang S, et al. The reduced soluble fibrinogen-like protein 2 and regulatory T cells in acute coronary syndrome. Exp Biol Med (Maywood). 2016;241(4):421–425. doi:10.1177/1535370215612138
   PubMed Web of Science ®Google Scholar
• Deng G, Song X, Greene MI. FoxP3 in Treg cell biology: a molecular and structural perspective. Clin Exp Immunol. 2020;199(3):255–262. doi:10.1111/cei.13357
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701–1711. doi:10.1084/jem.20060772
   PubMed Web of Science ®Google Scholar
• Atif M, Conti F, Gorochov G, Oo YH, Miyara M. Regulatory T cells in solid organ transplantation. Clin Transl Immunol. 2020;9(2):e01099. doi:10.1002/cti2.1099
   PubMed Web of Science ®Google Scholar
• Schmidt A, Rieger CC, Venigalla RK, et al. Analysis of FOXP3+ regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus. Immunol Res. 2017;65(2):551–563. doi:10.1007/s12026-017-8904-4
   PubMed Web of Science ®Google Scholar
• Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ regulatory T Cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50(2):302–316. doi:10.1016/j.immuni.2019.01.020
   PubMed Web of Science ®Google Scholar
• Dinh TN, Kyaw TS, Kanellakis P, et al. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation. 2012;126(10):1256–1266. doi:10.1161/CIRCULATIONAHA.112.099044
   PubMed Web of Science ®Google Scholar
• Foks AC, Frodermann V, Ter Borg M, et al. Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis. 2011;218(1):53–60. doi:10.1016/j.atherosclerosis.2011.04.029
   PubMed Web of Science ®Google Scholar
• Klingenberg R, Gerdes N, Badeau RM, et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest. 2013;123(3):1323–1334. doi:10.1172/JCI63891
   PubMed Web of Science ®Google Scholar
• Lü CX, Xu RD, Cao M, et al. FOXP3 demethylation as a means of identifying quantitative defects in regulatory T cells in acute coronary syndrome. Atherosclerosis. 2013;229(1):263–270. doi:10.1016/j.atherosclerosis
   PubMed Web of Science ®Google Scholar
• Jiang L, Chen F, Hu X, et al. Decreased helios expression in regulatory T Cells in acute coronary syndrome. Dis Markers. 2017;2017:7909407. doi:10.1155/2017/7909407
   PubMed Web of Science ®Google Scholar
• Attias M, Al-Aubodah T, Piccirillo CA. Mechanisms of human FoxP3+ Treg cell development and function in health and disease. Clin Exp Immunol. 2019;197(1):36–51. doi:10.1111/cei.13290
   PubMed Web of Science ®Google Scholar
• Ji QW, Guo M, Zheng JS, et al. Downregulation of T helper cell type 3 in patients with acute coronary syndrome. Arch Med Res. 2009;40(4):285–93. doi:10.1016/j.arcmed.2009.04.002
   Web of Science ®Google Scholar
• Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188(8):3869–3875. doi:10.4049/jimmunol.1103627
   PubMed Web of Science ®Google Scholar
• Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338–1342. doi:10.4049/jimmunol.1003081
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57. doi:10.1038/ni.1674
   PubMed Web of Science ®Google Scholar
• Momtazi-Borojeni AA, Abdollahi E, Nikfar B, Chaichian S, Ekhlasi-Hundrieser M. Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy. Heart Fail Rev. 2019;24(3):399–409. doi:10.1007/s10741-018-09764-z
   PubMed Web of Science ®Google Scholar
• Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019;124(1):150–160. doi:10.1161/CIRCRESAHA.118.311098
   PubMed Web of Science ®Google Scholar
• Chen X, Lu PH, Liu L, et al. TIGIT negatively regulates inflammation by altering macrophage phenotype. Immunobiology. 2016;221(1):48–55. doi:10.1016/j.imbio.2015.08.003
   PubMed Web of Science ®Google Scholar
• Munjal A, Khandia R. Atherosclerosis: orchestrating cells and biomolecules involved in its activation and inhibition. Adv Protein Chem Struct Biol. 2020;120:85–122. doi:10.1016/bs.apcsb.2019.11.002
   PubMed Web of Science ®Google Scholar
• Kuan R, Agrawal DK, Thankam FG. Treg cells in atherosclerosis. Mol Biol Rep. 2021;48(5):4897–4910. doi:10.1007/s1103021-06483-x
   PubMed Web of Science ®Google Scholar
• Ou HX, Guo BB, Liu Q, et al. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 2018;39(8):1249–1258. doi:10.1038/aps.2017.140
   PubMed Web of Science ®Google Scholar
• Shindo A, Tanemura H, Yata K, et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One. 2014;9(6):e100045. doi:10.1371/journal.pone.0100045
   PubMed Web of Science ®Google Scholar
• Hedin U, Matic LP. Recent advances in therapeutic targeting of inflammation in atherosclerosis. J Vasc Surg. 2019;69(3):944–951. doi:10.1016/j.jvs.2018.10.051
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(8):a028456. doi:10.1101/cshperspect.a028456
   PubMed Web of Science ®Google Scholar
• Zegeye MM, Andersson JSO, Wennberg P, Repsilber D, Sirsjö A, Ljungberg LU. IL-6 as a mediator of the association between traditional risk factors and future myocardial infarction: a Nested Case-Control Study. Arterioscler Thromb Vasc Biol. 2021;41(4):1570–1579. doi:10.1161/ATVBAHA.120.315793
   PubMed Web of Science ®Google Scholar
• Padilla-Gutiérrez JR, Valdés-Alvarado E, Rodríguez-Reyes SC, et al. Transforming Growth Factor Beta (TFG-β) Concentration Isoforms are Diminished in Acute Coronary Syndrome. Cell Biochem Biophys. 2018;76(3):433–439. doi:10.1007/s12013-018-0849-2
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hashizume M, Suzuki M, Mihara M. Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells. Eur J Pharmacol. 2010;634(1–3):178–183. doi:10.1016/j.ejphar.2010.02.026
   PubMed Web of Science ®Google Scholar
• Schinnerling K, Aguillón JC, Catalán D, Soto L. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin Exp Immunol. 2017;189(1):12–20. doi:10.1111/cei.12966
   PubMed Web of Science ®Google Scholar